Idioma:

NAFLD in normal weight individuals

DiStefano, Johanna K ; Gerhard, Glenn S

Diabetology and metabolic syndrome, 2022-03, Vol.14 (1), p.45-45, Article 45 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
NAFLD in normal weight individuals
Autor: DiStefano, Johanna K ; Gerhard, Glenn S
Assuntos: Asian people ; Biopsy ; BMI ; Body mass index ; Chronic illnesses ; Cirrhosis ; Clinical trials ; Comorbidity ; Development and progression ; East Asia ; Etiology ; Fatty liver ; Fibrosis ; Genetic factors ; Health aspects ; Insulin resistance ; Lean ; Liver ; Liver cirrhosis ; Liver diseases ; Medical research ; Medicine, Experimental ; Menopause ; Metabolic syndrome ; Metabolism ; Morbidity ; Mortality ; NAFLD ; NASH ; Nonobese ; Obesity ; Overweight ; Prevalence ; Review ; Risk assessment ; Type 2 diabetes
É parte de: Diabetology and metabolic syndrome, 2022-03, Vol.14 (1), p.45-45, Article 45
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Nonalcoholic fatty liver disease (NAFLD) can develop in lean individuals. Despite a better metabolic profile, the risk of disease progression to hepatic inflammation, fibrosis, and decompensated cirrhosis in the lean is similar to that in obesity-related NAFLD and lean individuals may experience more severe hepatic consequences and higher mortality relative to those with a higher body mass index (BMI). In the absence of early symptoms and abnormal laboratory findings, lean individuals are not likely to be screened for NAFLD or related comorbidities; however, given the progressive nature of the disease and the increased risk of morbidity and mortality, a clearer understanding of the natural history of NAFLD in lean individuals, as well as efforts to raise awareness of the potential health risks of NAFLD in lean individuals, are warranted. In this review, we summarize available data on NAFLD prevalence, clinical characteristics, outcomes, and mortality in lean individuals and discuss factors that may contribute to the development of NAFLD in this population, including links between dietary and genetic factors, menopausal status, and ethnicity. We also highlight the need for greater representation of lean individuals in NAFLD-related clinical trials, as well as more studies to better characterize lean NAFLD, develop improved screening algorithms, and determine specific treatment strategies based on underlying etiology.
Editor: England: BioMed Central Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

NAFLD in normal weight individuals

DiStefano, Johanna K ; Gerhard, Glenn S

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.